Click here for slides on this topic


Cardiovascular disease (CVD)

A constellation of diseases that affect the heart or blood vessels (veins and arteries), including atherosclerosis, arteriosclerosis, coronary heart disease (CHD), coronary artery disease (CAD), stroke, and heart failure, among others.


The following content matched the glossary term: Cardiovascular disease (CVD)

NDEI.org Expert Commentary Ed Horton, MD, on EMPA-REG OUTCOME Results

Top

Ed Horton, MD, discusses EMPA-REG OUTCOME results: SGLT2 inhibitor, empagliflozin, cuts CV deaths in high-risk type 2 diabetes patients

NDEI.org Expert Commentary Vivian Fonseca, MD, on EMPA-REG OUTCOME: Empagliflozin Cuts CV Deaths

Top

Vivian Fonseca, MD, discusses the impact of EMPA-REG OUTCOME; SGLT2 inhibitor, empagliflozin, reduced cardiovascular deaths in high-risk type 2 diabetes patients

Empagliflozin Cuts Cardiovascular Deaths in Landmark Trial

Top

The SGLT2 inhibitor, empagliflozin, reduces cardiovascular deaths in the EMPA-REG OUTCOME trial. Includes expert commentary.

Alirocumab Significantly Reduces LDL-C in High-Risk Patients in ODYSSEY FH I & FH II

Top

The PCSK9 inhibitor, alirocumab, significantly reduced LDL-C in high-risk patients with heterozygous FH in ODYSSEY FH I & FH II; from ESC 2015

No Heart Failure Risk With DPP-4 Inhibitor, Sitagliptin, in TECOS Subanalysis

Top

Data from a subanalysis of TECOS at ESC Congress 2015 confirms that the DPP-4 inhibitor, sitagliptin, does not cause heart failure in patients with type 2 diabetes. Includes expert commentary.

NDEI.org Expert Commentary Silvio Inzucchi MD on TECOS Subanalysis No Heart Failure Risk With Sitagliptin in High-Risk Type 2 Diabetes

Top

Silvio Inzucchi, MD, provides expert commentary on data from a subanalysis of TECOS, which confirmed that the DPP-4 inhibitor, sitagliptin, does not cause heart failure in patients with type 2 diabetes; from ESC Congress 2015.

NDEI.org Expert Commentary Silvio Inzucchi MD on IMPROVE-IT Subanalysis CV Benfits of Ezetimibe Exclusive to Subjects With Diabetes

Top

Silvio Inzucchi, MD, provides expert commentary on data from a subanalysis of IMPROVE-IT that showed the cardiovascular benefits of ezetimibe are restricted to patients with type 2 diabetes; from ESC Congress 2015.

CV Benefits of Ezetimibe Favor Patients With Type 2 Diabetes in IMPROVE-IT Analysis

Top

Data from a subanalysis of IMPROVE-IT at ESC Congress 2015 show that the cardiovascular benefits of ezetimibe are exclusive to individuals with type 2 diabetes. Includes expert commentary.

AHA ADA prevention of CVD in T2D - Hypoglycemia & CVD

Top

Summary of evidence for hypoglycemia & cardiovascular disease (CVD) from the AHA ADA CVD prevention in type 2 diabetes guidelines.

AHA ADA prevention of CVD in T2D - Kidney Disease

Top

Summary of recommendations for management of kidney disease from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Cardiovascular disease (CVD) Slides Found: 69
Hypertension and Glucose Tolerance in Four Ethnic Groups
Assessing Risk: Is Measurement of Waist Circumference Necessary?
Meta-Analysis: A1C and CVD in Type 2 Diabetes
ARIC: Association Between MetS Components and CHD Risk
CARDIA: Fast-Food Frequency and Insulin Resistance
Metabolic and Vascular Actions of PPAR-alpha and PPAR-gamma Agonists
FHS: Comparison of Incidence Rates for CVD Events
PROactive: Objective/Endpoints
PROactive: Time to Primary Composite Endpoint
PROactive: Time to Main Secondary Composite Endpoint (Death, Nonfatal MI, or Stroke)
Prevalence of IFG in Nondiabetic US Adolescents (Aged 12–19 Yrs)
Waist Circumference, TG Levels Predict Future MetS in 18- to 19-Yr-Old Females
INTERHEART: Waist-to-Hip Ratio Is a Better Predictor for MI Than BMI
DCCT/EDIC: Incidence of Any Cardiovascular Disease Outcome
DCCT/EDIC: Incidence of Nonfatal MI, Stroke, or Death
SPARCL: Primary Outcome of Fatal or Nonfatal Stroke
SPARCL: First Events
Proportion of Diabetic Patients With Low HDL-C Stratified by Treatment, Sex, and Cardiovascular Disease
Risk of CVD Mortality Risk rate Among Men with MetSyn and Diabetes, Alone and in Combination
Hazard Ratios of CVD Mortality Among Men With MetSyn and Diabetes, Alone and in Combination
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
Statin Use and Risk for Diabetes: Design
Statin Use and Risk for Diabetes: Results
Incidence of CVD in Patients With Type 2 Diabetes and No CVD History
CVD Event Prediction in Patients With Type 2 Diabetes and No CVD History
Look AHEAD: Design
Can Coronary Artery Calcium Predict CVD Outcomes in Type 2 Diabetes?
CAC and CVD Mortality in Type 2 Diabetes: Diabetes Heart Study
Diabetes Heart Study: CAC and CVD Mortality
Diabetes Heart Study: Odds Ratios for CVD Mortality
PREDIMED: Mediterranean Diet for Primary Prevention of CVD
ACCORD: Factors Associated with Increased Hypoglycemia Risk in Intensive and Standard Treatment Arms
Meta-Analysis: Severe Hypoglycemia Associated with ~2x Risk for CVD
Diabetes Surgery Study: Design
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD Secondary Endpoint
SAVOR-TIMI 53: Saxagliptin Increased Hospitalization for Heart Failure
SAVOR-TIMI 53: Significantly Better Glycemic Control with Saxagliptin
SAVOR-TIMI 53: Safety Endpoints
SAVOR-TIMI 53: Design
AHA/ACC/TOS Obesity Guidelines: Identifying Candidates for Weight Loss
VA BEACH DIET Study: Impact of Diet on CVD Risk | NDEI
Teen-LABS CVD Risk in Adolescents Undergoing Bariatric Surgery | NDEI
CVD Treatment Statin ADA Type 1 Diabetes Guidelines | NDEI
AHA ADA Guidelines Diabetes CVD PPT | NDEI
AHA ADA Diabetes Diagnosis Criteria Guidelines PPT | NDEI
Lifestyle Management for CVD Prevention in Diabetes AHA ADA | NDEI
Lifestyle for Weight Loss in Diabetes AHA ADA Guidelines | NDEI
Pharmacologic Therapy for Weight Loss Type 2 Diabetes AHA ADA | NDEI
Diabetes Medications & Weight AHA ADA CVD Prevention Guidelines | NDEI
Bariatric Metabolic Surgery for Weight Loss Type 2 Diabetes AHA ADA | NDEI
Bariatric Surgery for Weight Loss in Type 2 Diabetes for CVD Prevention | NDEI
Individualized Diabetes Therapy for CVD Prevention in Type 2 Diabetes AHA ADA | NDEI
A1C Targets AHA ADA Guidelines Type 2 Diabetes CVD Prevention | NDEI
Type 2 Diabetes & CVD Risk AHA ADA Guidelines PPT | NDEI
Blood Pressure Targets Type 2 Diabetes AHA ADA Guidelines | NDEI
Cholesterol Targets LDL Type 2 Diabetes AHA ADA Guidelines | NDEI
Aspirin Therapy Type 2 Diabetes CVD Prevention PPT | NDEI
Kidney Disease in Type 2 Diabetes for CVD Prevention PPT | NDEI
Hypoglycemia & CVD Risk Type 2 Diabetes AHA ACC Guidelines PPT | NDEI
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD
EMPA-REG OUTCOME Empagliflozin CV Death Reduced Type 2 Diabetes | NDEI
Empagliflozin Reduces Death Type 2 Diabetes EMPA-REG OUTCOME EASD | NDEI
EMPA-REG OUTCOME Empagliflozin Heart Failure Type 2 Diabetes EASD | NDEI
EMPA-REG OUTCOME Empagliflozin A1C High-Risk Type 2 Diabetes | NDEI
Empagliflozin Safety Adverse Events Type 2 Diabetes EMPA-REG OUTCOME | NDEI
EMPA-REG OUTCOME Design Empagliflozin SGLT2 Type 2 Diabetes | NDEI